Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma.
PD-1 inhibition
cutaneous squamous carcinoma
immunotherapy
pseudoprogression
second primary tumors (SPTs)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
01
2021
accepted:
22
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blockade. We highlight treatment issues distinct to the management of the disease including expansion of the traditional concept of pseudoprogression and describe delayed responses after immune-specific response criteria confirmed progressive disease with and without clinical deterioration. We term this phenomenon "delayed response after confirmed progression (DR)". We also discuss the common development of second primary tumors, heterogeneous disease responses, and expanding clinical boundaries for immunotherapy use.
Identifiants
pubmed: 33937066
doi: 10.3389/fonc.2021.656611
pmc: PMC8081898
doi:
Types de publication
Journal Article
Langues
eng
Pagination
656611Informations de copyright
Copyright © 2021 Lim, Cavanagh, Hicks, McLean, Goh, Webb and Rischin.
Déclaration de conflit d'intérêts
AL –Uncompensated advisory board7 from Merck Sharp & Dohme and Bristol-Myers Squibb with travel and accommodation expenses; uncompensated consultancy for Eisai. RH - Shareholder in Telix Pharmaceuticals with honoraria and any dividends donated to the Peter MacCallum Cancer Centre. DR - Institutional research grant and trial funding from Regeneron Pharmaceuticals, Inc., Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, and GlaxoSmithKline, Sanofi; uncompensated scientific committee and advisory board from Merck Sharp & Dohme, Regeneron Pharmaceuticals, Inc., Sanofi, GlaxoSmithKline, and Bristol-Myers Squibb, and travel and accommodation from Merck Sharp & Dohme and GlaxoSmithKline. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2018 Mar 20;36(9):850-858
pubmed: 29341833
Sci Transl Med. 2016 Jul 6;8(346):346ra92
pubmed: 27384348
Cancer Immunol Immunother. 2009 Aug;58(8):1297-306
pubmed: 19139884
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
JAMA Oncol. 2019 Dec 1;5(12):1769-1773
pubmed: 31158272
Clin Cancer Res. 2013 Jul 15;19(14):3936-43
pubmed: 23743568
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911
Clin Cancer Res. 2018 May 15;24(10):2268-2275
pubmed: 29326281
J Clin Oncol. 2018 Jul 1;36(19):1905-1912
pubmed: 29746230
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Clin Oncol. 2015 Nov 1;33(31):3541-3
pubmed: 26261262
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Liver Cancer. 2019 Nov;8(6):480-490
pubmed: 31799205
J Clin Oncol. 2021 Jan 1;39(1):1-3
pubmed: 32986527
J Immunother Cancer. 2019 Jul 24;7(1):196
pubmed: 31340861
Lancet Oncol. 2008 Aug;9(8):713-20
pubmed: 18617440
J Clin Oncol. 2021 Jan 1;39(1):30-37
pubmed: 32822275
Int J Clin Oncol. 2013 Jun;18(3):506-9
pubmed: 22534799
J Clin Oncol. 2020 Sep 1;38(25):2916-2925
pubmed: 32673170
JAMA Oncol. 2017 Nov 1;3(11):1511-1519
pubmed: 28662232
Cell. 2019 Sep 19;179(1):219-235.e21
pubmed: 31522890
F1000Res. 2018 Jun 1;7:
pubmed: 29904586
Nat Cancer. 2020 Apr;1:423-436
pubmed: 33521652
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32554615
J Clin Oncol. 2007 May 1;25(13):1753-9
pubmed: 17470865
Cell. 2020 Jul 23;182(2):497-514.e22
pubmed: 32579974
Nat Med. 2021 Jan;27(1):141-151
pubmed: 33398161
Nat Commun. 2020 Feb 18;11(1):931
pubmed: 32071302
Lancet Oncol. 2019 Jul;20(7):948-960
pubmed: 31160251
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
NPJ Precis Oncol. 2020 Jun 3;4:13
pubmed: 32550269
Lancet Oncol. 2020 Feb;21(2):294-305
pubmed: 31952975
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
Med J Aust. 2017 Oct 16;207(8):339-343
pubmed: 29020905
Ann Oncol. 2018 Oct 1;29(10):2115-2120
pubmed: 30137228
J Invest Dermatol. 2009 Feb;129(2):323-8
pubmed: 18668137
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2020 Sep 10;38(26):3051-3061
pubmed: 32730186
J Immunother Cancer. 2018 Oct 23;6(1):112
pubmed: 30352626